Therapeutic Targeting of ATR in Cancer
Author:
Publisher
Springer International Publishing
Link
https://link.springer.com/content/pdf/10.1007/16833_2024_318
Reference97 articles.
1. Abuetabh Y, Wu HH, Chai C, Al Yousef H, Persad S, Sergi CM, Leng R (2022) DNA damage response revisited: the p53 family and its regulators provide endless cancer therapy opportunities. Exp Mol Med 54:1658–1669
2. Ali R, Alblihy A, Toss MS, Algethami M, Al Sunni R, Green AR, Rakha EA, Madhusudan S (2020) XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib. Ther Adv Med Oncol 12:1758835920974201
3. Ao W, Im Kim H, Tommarello D, Conrads KA, Hood BL, Litzi T, Abulez T, Teng P, Dalgard CL, Zhang X, Wilkerson MD, Darcy KM, Tarney CM, Phippen NT, Bakkenist CJ, Maxwell GL, Conrads TP, Risinger JI, Bateman NW (2023) Metronomic dosing of ovarian cancer cells with the ATR inhibitor AZD6738 leads to loss of CDC25A expression and resistance to ATRi treatment. J Gynecol Oncol 177:60–71
4. Barnieh FM, Loadman PM, Falconer RA (2021) Progress towards a clinically-successful ATR inhibitor for cancer therapy. Curr Res Pharmacol Drug Discov 2:100017
5. Baschnagel AM, Elnaggar JH, VanBeek HJ, Kromke AC, Skiba JH, Kaushik S, Abel L, Clark PA, Longhurst CA, Nickel KP, Leal TA (2021) ATR inhibitor M6620 (VX-970) enhances the effect of radiation in non–small cell lung cancer brain metastasis patient-derived xenografts. Mol Cancer Ther 20:2129–2139
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3